Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Syndax Pharmaceuticals reported its financial results for Q4 and the full year 2024, highlighting $7.7 million in net product revenue from Revuforj (revumenib) in the first five weeks of its launch.
March 03, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals reported $7.7 million in revenue from Revuforj in the first five weeks of its launch, indicating strong initial market reception.
The $7.7 million revenue from Revuforj in a short period suggests a successful product launch, likely boosting investor confidence and positively impacting SNDX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100